After a finite number of divisions, cells simply give up. As each round of replication trims their telomeres—the protective ...

When two cells "talk" to each other, they often do so through tiny channels called electrical synapses. Unlike chemical ...

The mechanism of HIV-1 genome uncoating is currently not well understood. This work shows that capsid-targeting drugs lay ...

OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale patient-derived biology, announced that data ...

To help Class 9 students score high marks in the Annual Exam 2026, we have compiled complete CBSE Class 9 Study Material 2025 ...

A new study describes a key molecular mechanism that explains how cells exchange information through extracellular vesicles (EVs), small particles with great therapeutic potential.

Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.

Sonrotoclax has received FDA priority review for relapsed or refractory mantle cell lymphoma, indicating potential substantial treatment improvement. The BGB-11417-201 study demonstrated significant ...

(Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.